Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epaminurad vs Febuxostat in Gout Patients
NCT05815901Phase 3Completed
- Sponsor
- JW Pharmaceutical Corporation
- Start
- Mar 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of epaminurad in gout, sponsored by JW Pharmaceutical Corporation. Started Mar 2023; status: completed.
02
Drugs
epaminurad
03
Conditions
gout
Beyond the preview
Go deeper on NCT05815901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05815901.